Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ibuprofen use may reduce Parkinson’s risk : New Harvard study
The study, followed more than 130,000 people for six years, revealed that people who used three or more tablets of ibuprofen each week were about 38% less likely
The study, followed more than 130,000 people for six years, revealed that people who used three or more tablets of ibuprofen each week were about 38% less likely
Globe Laboratories brings to the partnership its expertise in biopharmaceutical drugs manufacturing and development, and experience in late stage drug development. National Pharmaceuticals president and CEO Elaine Affleck
In the trial, the company will evaluate the safety and efficacy of Prochymal in conjunction with standard of care in improving heart function in patients who experienced their
FDA said the CRL was issued based on the results from Clarity study. However, the FDA has requested EMD Serono to provide an improved understanding of safety risks
UCB net profit was EUR103m for the full-year of 2010, compared to EUR513m for the same period in 2009. Net sales for the full-year of 2010 were EUR2.78bn,
As per the agreement, Charles River is expected to take up the responsibility for supplying the research models throughout a range of therapeutic areas like neuroscience, diabetes and
With the new design, the company’s familiar brands including Kendall, Valleylab, Mallinckrodt and Nellcor are shown under the Covidien name. The new Covidien packaging will be standardized throughout
With this approval Bristol-Myers Squibb get marketing authorization right for Baraclude in 27 countries of the European Union. According to the company, the approval is based on a
Perrigo is a global healthcare supplier engaged in developing, manufacturing and distributing OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, active pharmaceutical ingredients (API) and pharmaceutical
The study is a 19-week follow-up, multicentre, double-blind, randomised, placebo-controlled, parallel-group study in subjects with MS spasticity not fully relieved with current anti-spasticity therapy. The trial result suggested